GIST Clinical Trials (April 2026): 28 Recruiting Interventional Studies

Last updated: April 19, 2026

Current Clinical Trial Landscape

About gastrointestinal stromal tumor (GIST):

GIST is the most common mesenchymal tumor of the GI tract. ~85% have KIT or PDGFRA mutations. Highly responsive to tyrosine kinase inhibitors (TKIs). SDH-deficient GIST is a distinct subtype requiring different approaches.

Active research areas in 2026:

TKI optimization: adjuvant duration, ctDNA-guided therapy
Novel TKIs: IDRX-42, DCC-3009, olverembatinib
SDH-deficient GIST-specific therapies
Antibody-drug conjugates (c-Kit ADC)

Standard of care: Localized: surgery ± adjuvant imatinib (3 years for high-risk). Metastatic: imatinib 1st line → sunitinib 2nd line → regorafenib 3rd line → ripretinib 4th line.

Recruiting Trials by Treatment Setting

Adjuvant Therapy

After surgery for resectable GIST:

NCT05385549 - 5 years adjuvant imatinib (extended duration)
NCT05009927 - Imatinib after 10 years of treatment

First-Line Metastatic

For newly diagnosed metastatic/unresectable GIST:

NCT05493215 - Imatinib therapeutic drug monitoring (TDM)

Second-Line and Beyond

After progression on imatinib:

NCT07218926 - IDRX-42 vs sunitinib (Phase 3)
NCT05366816 - ctDNA-guided sunitinib and regorafenib
NCT05905887 - Rivoceranib plus paclitaxel

Trials by Treatment Approach

Novel TKIs

Next-generation tyrosine kinase inhibitors targeting resistant mutations:

NCT05489237 - IDRX-42 first-in-human (Phase 1)
NCT06629234 - DCC-3009 master protocol
NCT03594422 - HQP1351 (olverembatinib)
NCT06654246 - Ziftomenib + imatinib combination

SDH-Deficient GIST

Trials specifically for SDH-deficient/wild-type GIST (no KIT/PDGFRA mutations):

NCT06640361 - Olverembatinib in SDH-deficient GIST (Phase 3)
NCT05661643 - Temozolomide in SDH-deficient GIST

Antibody-Drug Conjugates

NCT06805825 - NN3201 (c-Kit specific ADC)

Combination Therapies

NCT05957367 - Inlexisertib (DCC-3116) combinations
NCT06380816 - UCB4594 in advanced cancers

View all 28 GIST trials on ClinicalTrials.gov →

Frequently Asked Questions

How do I find GIST clinical trials I'm eligible for?

Paste your medical summary into ClinTrialFinder to get AI-matched GIST trials in minutes. The tool considers your KIT or PDGFRA mutation type, prior TKI treatments, and disease status.

What GIST trials are currently recruiting?

There are 28 recruiting interventional trials for gastrointestinal stromal tumors including next-generation TKIs, immunotherapy combinations, and novel targeted agents.

Find GIST Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific mutation status and treatment history.

Find Matching Trials